Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VRCA Verrica Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: VRCA
Price (delayed)
$0.4479
Market cap
$41.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.48
Enterprise value
$40.72M
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and
Highlights
The EPS is up by 20% since the previous quarter
VRCA's debt is down by 2.5% QoQ
The equity has dropped by 150% year-on-year but it has surged by 71% since the previous quarter
The quick ratio has plunged by 63% YoY but it has increased by 45% from the previous quarter
The gross margin has decreased by 25% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of VRCA
Market
Valuations
Earnings
Shares outstanding
91.78M
Market cap
$41.11M
Enterprise value
$40.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.38
Revenue
$7.57M
Gross profit
$4.83M
Operating income
-$65.92M
Net income
-$76.58M
EBIT
-$67.17M
EBITDA
-$65.9M
Free cash flow
-$60.95M
Per share
Balance sheet
Liquidity
EPS
-$1.48
EPS diluted
-$1.48
Free cash flow per share
-$1.18
Book value per share
-$0.22
Revenue per share
$0.15
TBVPS
$1.04
Total assets
$54.13M
Total liabilities
$63.99M
Debt
$45.94M
Equity
-$9.86M
Working capital
$22.17M
Debt to equity
-4.66
Current ratio
1.76
Quick ratio
1.6
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
-871%
Gross margin
63.8%
Net margin
-1,012.1%
Operating margin
-871.3%
Return on assets
-149.1%
Return on equity
N/A
Return on invested capital
-177.3%
Return on capital employed
-267.4%
Return on sales
-887.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRCA stock price
How has the Verrica Pharmaceuticals stock price performed over time
Intraday
7.88%
1 week
-4.5%
1 month
-3.24%
1 year
-94.29%
YTD
-36.01%
QTD
1.29%
Financial performance
How have Verrica Pharmaceuticals's revenue and profit performed over time
Revenue
$7.57M
Gross profit
$4.83M
Operating income
-$65.92M
Net income
-$76.58M
Gross margin
63.8%
Net margin
-1,012.1%
The revenue rose by 48% year-on-year but it has declined by 18% since the previous quarter
Verrica Pharmaceuticals's operating margin has increased by 32% YoY but it has decreased by 3.3% from the previous quarter
Verrica Pharmaceuticals's gross profit has decreased by 29% from the previous quarter but it has increased by 10% YoY
The gross margin has decreased by 25% YoY and by 14% from the previous quarter
Price vs fundamentals
How does VRCA's price correlate with its fundamentals
Growth
What is Verrica Pharmaceuticals's growth rate over time
Valuation
What is Verrica Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.38
The EPS is up by 20% since the previous quarter
The equity has dropped by 150% year-on-year but it has surged by 71% since the previous quarter
The stock's price to sales (P/S) is 95% less than its 5-year quarterly average of 61.4 and 83% less than its last 4 quarters average of 16.9
The revenue rose by 48% year-on-year but it has declined by 18% since the previous quarter
Efficiency
How efficient is Verrica Pharmaceuticals business performance
The return on assets has dropped by 72% year-on-year and by 2.1% since the previous quarter
The return on invested capital has increased by 32% year-on-year
The ROS is up by 28% year-on-year but it is down by 8% since the previous quarter
Dividends
What is VRCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRCA.
Financial health
How did Verrica Pharmaceuticals financials performed over time
Verrica Pharmaceuticals's total assets is 15% lower than its total liabilities
Verrica Pharmaceuticals's total assets has surged by 64% QoQ but it has decreased by 34% YoY
The quick ratio has plunged by 63% YoY but it has increased by 45% from the previous quarter
The equity has dropped by 150% year-on-year but it has surged by 71% since the previous quarter
VRCA's debt is down by 2.5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.